RETA (GLP-3) 30mg Per Vial

What is RETA (GLP-3)?

RETA (GLP-3) is an investigational metabolic peptide being studied for its activity across three important hormonal pathways: GLP-1, GIP and glucagon receptors. This combination has made RETA an exciting area of current metabolic research, particularly in relation to energy balance, glucose regulation, appetite signalling and body composition.

Unlike compounds that act primarily through a single metabolic pathway, RETA allows researchers to investigate the interaction between three complementary signalling systems within one molecule.

Why is RETA interesting?

The three pathways targeted by RETA each have important roles in human metabolism.

• GLP-1 is involved in glucose-dependent insulin secretion, appetite signalling and gastrointestinal regulation.
  
  
• GIP is an incretin hormone involved in nutrient sensing and insulin secretion and is increasingly being studied for its broader metabolic effects.
  
  
• Glucagon plays an important role in hepatic metabolism, energy mobilisation and the body’s response to changing energy demands.

The combination of these pathways is what makes RETA particularly interesting to researchers investigating metabolic regulation.

RETA & GLP-1 Signalling

GLP-1 is naturally released in response to food intake and plays an important role in glucose homeostasis. GLP-1 receptor signalling influences glucose-dependent insulin secretion, glucagon regulation, gastrointestinal activity and appetite-related pathways. RETA provides researchers with an opportunity to investigate GLP-1 activity alongside GIP and glucagon signalling rather than studying these pathways independently.

RETA & GIP Signalling

GIP, or glucose-dependent insulinotropic polypeptide, is another naturally occurring incretin hormone. GIP responds to nutrient intake and contributes to glucose-dependent insulin secretion. Researchers are increasingly interested in how GIP signalling interacts with GLP-1 signalling and how these pathways may complement one another.

RETA & Glucagon

Glucagon is an important regulator of energy availability and hepatic metabolism. It influences processes involved in mobilising stored energy and regulating substrate utilisation. The addition of glucagon receptor activity creates an interesting research model for investigating the relationship between energy expenditure, fuel utilisation and incretin signalling.

RETA & Metabolic Research

RETA has progressed into advanced clinical research, with Phase 3 studies investigating its effects in obesity and related metabolic conditions. Recent Phase 3 results have reported substantial changes in body weight and glycaemic measures in studied populations, while the compound remains investigational and is not yet approved for public use.

These findings have increased interest in RETA’s unique triple-receptor mechanism and its potential role in future metabolic research.

What makes RETA different?

• Triple-receptor activity — Research into GLP-1, GIP and glucagon signalling simultaneously.
  
  
• Metabolic signalling — Investigation into several interconnected pathways involved in energy regulation.
  
  
• Appetite research — Study of hormonal pathways involved in food intake and satiety.
  
  
• Energy-balance research — Investigation into the relationship between energy intake, expenditure and substrate utilisation.
  
  
• Body-composition research — Study of changes in body weight and metabolic parameters.

A new direction in metabolic research

RETA represents an exciting direction in metabolic science because it brings together three major hormonal pathways within a single investigational molecule. The research continues to develop, with ongoing studies examining its longer-term effects, safety profile and potential applications.

Research Areas at a Glance

GLP-1 Signalling • GIP Signalling • Glucagon Receptor • Metabolic Regulation • Appetite Research • Energy Balance • Body Composition

Research Disclaimer: RETA is an investigational compound intended for scientific research and is not currently approved by SAHPRA, the FDA, or other major regulatory authorities for therapeutic or consumer applications. Peptigen products are provided exclusively for laboratory research. Information on this website is presented for general scientific and educational purposes and should not be considered medical advice, a treatment recommendation, or guidance for personal use. Peptigen does not provide dosing, administration or reconstitution guidance for research compounds. Purchasers are responsible for ensuring that research materials are handled within an appropriate research environment and in accordance with relevant laws, regulations, laboratory protocols and safety requirements. Research use only.

Peptigen.
Quality. Research. Potential.